Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: A report by the American academy of ophthalmology

Allen C. Ho, Ingrid Scott, Stephen J. Kim, Gary C. Brown, Melissa M. Brown, Michael S. Ip, Franco M. Recchia

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Objective: To review the evidence regarding the safety and efficacy of current anti-vascular endothelial growth factor (VEGF) pharmacotherapies for the treatment of diabetic macular edema (DME). Methods: Literature searches last were conducted in September 2011, in PubMed with no date restrictions, limited to articles published in English, and in the Cochrane Library without a language limitation. The combined searches yielded 532 citations, of which 45 were deemed clinically relevant for the authors to review in full text and to assign ratings of level of evidence to each of the selected studies with the guidance of the panel methodologists. Results: At this time, there are 5 studies that provide level I evidence for intravitreal ranibizumab, alone or in combination with other treatments for DME. There is also 1 study that provides level I evidence for intravitreal pegaptanib sodium for DME. Nine studies reviewed were rated as level II, and 2 additional studies reviewed were graded as level III. Most studies do not provide information about long-term results (i.e., more than 2 years of follow-up) or the comparative efficacy of anti-VEGF pharmacotherapies. Conclusions: Review of the available literature indicates that anti-VEGF pharmacotherapy, delivered by intravitreal injection, is a safe and effective treatment over 2 years for DME. Further evidence is required to support the long-term safety of these pharmacotherapies and their comparative efficacy. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

Original languageEnglish (US)
Pages (from-to)2179-2188
Number of pages10
JournalOphthalmology
Volume119
Issue number10
DOIs
StatePublished - Jan 1 2012

Fingerprint

Macular Edema
Ophthalmology
Vascular Endothelial Growth Factor A
Drug Therapy
Disclosure
Safety
Intravitreal Injections
PubMed
Libraries
Language
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Ho, Allen C. ; Scott, Ingrid ; Kim, Stephen J. ; Brown, Gary C. ; Brown, Melissa M. ; Ip, Michael S. ; Recchia, Franco M. / Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema : A report by the American academy of ophthalmology. In: Ophthalmology. 2012 ; Vol. 119, No. 10. pp. 2179-2188.
@article{c3c8ac29922e4b34b9758ec53345d4c1,
title = "Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: A report by the American academy of ophthalmology",
abstract = "Objective: To review the evidence regarding the safety and efficacy of current anti-vascular endothelial growth factor (VEGF) pharmacotherapies for the treatment of diabetic macular edema (DME). Methods: Literature searches last were conducted in September 2011, in PubMed with no date restrictions, limited to articles published in English, and in the Cochrane Library without a language limitation. The combined searches yielded 532 citations, of which 45 were deemed clinically relevant for the authors to review in full text and to assign ratings of level of evidence to each of the selected studies with the guidance of the panel methodologists. Results: At this time, there are 5 studies that provide level I evidence for intravitreal ranibizumab, alone or in combination with other treatments for DME. There is also 1 study that provides level I evidence for intravitreal pegaptanib sodium for DME. Nine studies reviewed were rated as level II, and 2 additional studies reviewed were graded as level III. Most studies do not provide information about long-term results (i.e., more than 2 years of follow-up) or the comparative efficacy of anti-VEGF pharmacotherapies. Conclusions: Review of the available literature indicates that anti-VEGF pharmacotherapy, delivered by intravitreal injection, is a safe and effective treatment over 2 years for DME. Further evidence is required to support the long-term safety of these pharmacotherapies and their comparative efficacy. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.",
author = "Ho, {Allen C.} and Ingrid Scott and Kim, {Stephen J.} and Brown, {Gary C.} and Brown, {Melissa M.} and Ip, {Michael S.} and Recchia, {Franco M.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.ophtha.2012.07.058",
language = "English (US)",
volume = "119",
pages = "2179--2188",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "10",

}

Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema : A report by the American academy of ophthalmology. / Ho, Allen C.; Scott, Ingrid; Kim, Stephen J.; Brown, Gary C.; Brown, Melissa M.; Ip, Michael S.; Recchia, Franco M.

In: Ophthalmology, Vol. 119, No. 10, 01.01.2012, p. 2179-2188.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema

T2 - A report by the American academy of ophthalmology

AU - Ho, Allen C.

AU - Scott, Ingrid

AU - Kim, Stephen J.

AU - Brown, Gary C.

AU - Brown, Melissa M.

AU - Ip, Michael S.

AU - Recchia, Franco M.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Objective: To review the evidence regarding the safety and efficacy of current anti-vascular endothelial growth factor (VEGF) pharmacotherapies for the treatment of diabetic macular edema (DME). Methods: Literature searches last were conducted in September 2011, in PubMed with no date restrictions, limited to articles published in English, and in the Cochrane Library without a language limitation. The combined searches yielded 532 citations, of which 45 were deemed clinically relevant for the authors to review in full text and to assign ratings of level of evidence to each of the selected studies with the guidance of the panel methodologists. Results: At this time, there are 5 studies that provide level I evidence for intravitreal ranibizumab, alone or in combination with other treatments for DME. There is also 1 study that provides level I evidence for intravitreal pegaptanib sodium for DME. Nine studies reviewed were rated as level II, and 2 additional studies reviewed were graded as level III. Most studies do not provide information about long-term results (i.e., more than 2 years of follow-up) or the comparative efficacy of anti-VEGF pharmacotherapies. Conclusions: Review of the available literature indicates that anti-VEGF pharmacotherapy, delivered by intravitreal injection, is a safe and effective treatment over 2 years for DME. Further evidence is required to support the long-term safety of these pharmacotherapies and their comparative efficacy. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

AB - Objective: To review the evidence regarding the safety and efficacy of current anti-vascular endothelial growth factor (VEGF) pharmacotherapies for the treatment of diabetic macular edema (DME). Methods: Literature searches last were conducted in September 2011, in PubMed with no date restrictions, limited to articles published in English, and in the Cochrane Library without a language limitation. The combined searches yielded 532 citations, of which 45 were deemed clinically relevant for the authors to review in full text and to assign ratings of level of evidence to each of the selected studies with the guidance of the panel methodologists. Results: At this time, there are 5 studies that provide level I evidence for intravitreal ranibizumab, alone or in combination with other treatments for DME. There is also 1 study that provides level I evidence for intravitreal pegaptanib sodium for DME. Nine studies reviewed were rated as level II, and 2 additional studies reviewed were graded as level III. Most studies do not provide information about long-term results (i.e., more than 2 years of follow-up) or the comparative efficacy of anti-VEGF pharmacotherapies. Conclusions: Review of the available literature indicates that anti-VEGF pharmacotherapy, delivered by intravitreal injection, is a safe and effective treatment over 2 years for DME. Further evidence is required to support the long-term safety of these pharmacotherapies and their comparative efficacy. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

UR - http://www.scopus.com/inward/record.url?scp=84867096307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867096307&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2012.07.058

DO - 10.1016/j.ophtha.2012.07.058

M3 - Article

C2 - 22917890

AN - SCOPUS:84867096307

VL - 119

SP - 2179

EP - 2188

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 10

ER -